Immunovaccine hires John Trizzino as ceo

Vaccine specialist brings 25 years of experience to the role

Immunovaccine, a Canadian developer of vaccines, has appointed John Trizzino as chief executive. He will also join the board of directors of the firm upon joining on 1 October.

Trizzino has focused his career on vaccine development, manufacturing and distribution in the US and worldwide.

He joins Immunovaccine from Novavax, a clinical-stage vaccine company in Rockville, Maryland, where he was senior vice president.

Prior to this, he held senior executive positions at MedImmune, acquired by AstraZeneca, and ID BioMedical, now part of GlaxoSmithKline.

He began his broad-based career in vaccines at Henry Schein.

‘As our development programme accelerates with a second cancer vaccine in the clinic, we are pleased to be joined by someone with John's experience in partnering, licensing and distribution,’ said Albert Scardino, chairman of Immunovaccine.

‘The next phase of our development includes expanding the commercial potential of our early stage research partnerships. That is John's specialism. He knows the public markets, private financing and government contracting, and with his broad experience in the biotechnology industry, we anticipate a high level of visibility for our pioneering delivery platform and our vaccines.’

Immunovaccine develops vaccines for treating cancer and for the prevention of infectious disease.

The firm's DepoVax platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Immunovaccine licenses cancer vaccine from Merck KGaA

Builds on clinical studies by formulating vaccine in DepoVax system
Pharmaceutical

Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU

The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Pharmaceutical

Driving excellence in aseptic fill-finish

Driving excellence in aseptic fill-finish | 3P innovation's strategic partnership with Stäubli Robotics
Manufacturing

Alex Jezequel talks about designing roboFIL

Interview with Alex Jezequel, Projects Director at 3P innovation: roboFIL: revolutionising pharmaceutical fill-finish operations
Regulatory

The foundations of pharmaceutical compliance for beginners

Whether you’re stepping into the pharmaceutical industry for the first time or pivoting into a compliance or quality assurance role after years of experience, mastering the fundamentals of quality and regulatory compliance is vital to your success—and to the success of your organisation
Manufacturing

WLS introduces PR-12 and PR-24 plunger rod insertion and labelling systems

By improving reliability and streamlining production, the PR-12 and PR-24 help pharmaceutical manufacturers and contract packers protect product quality and reduce waste while maximising operational efficiencies
Subscribe now